384 results about "Tranexamic acid" patented technology

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The invention discloses skin age multi-effect silk mask liquid which is prepared by mixing hydrosolvent, humectant, skin conditioner, preservative, thickener and ph regulator. The humectant comprises glycerin, propylene glycol, butylene glycol, maltooligosyl glucoside, hydrogenated starch hydrolysate, glyceryl polymethacrylate, PVMMA copolymer, sodium hyaluronate, betaine and baobab pulp extract, and the skin conditioner comprises nicotinamide, Herba portulacae extract, polyquaternium-51, soybean polypeptide, blackberry leaf extract, purple coneflower extract, Aloe vera extract, European horse chestnut extract, nonapeptide-1, tranexamic acid, Herba centella extract, ceramide 1, palmitoyl pentapeptide-4, oligopeptide-1, carnosine and dipotassium glycyrrhizinate. The mask liquid prepared by applying the component ratio can effectively realize efficacy of moisturizing and whitening facial skin, is free of irritation to the facial skin and has good whitening effect.

A composition which comprises (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and, as occasion demands, (iii) L-ascorbic acid, a derivative thereof or a salt thereof.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The invention discloses a cosmetic and a preparation method thereof. The cosmetic is prepared from five components of A, B, C, D and E. The cosmetic is composed of thirty raw materials including deionized water, hydroxyethyl cellulose, allantoin, carbopol U20, propanediol, 1,3-butanediol, sodium hyaluronate, an aloe vera extract, a natto extract, asiaticoside, vitamin C, bisabolol, an amino acid humectant, D-panthenol, VC ethyl ether, nicotinamide, glabridin, tranexamic acid, ceramide, algal polysaccharide, glucan, dipotassium glycyrrhizinate, an epidermal growth factor (EGF), triethanolamine, isothiazolinone, essence, squalane, jojoba oil, vitamin E oil and crystal sparkling pearl powder. The cosmetic has the functions of making skins fine and smooth, brightening the skins, repairing sensitive skins, controlling oil, toning skins and modifying skin blemishes, has no side effect or no dependence, and does not threaten health of a human body.

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

The present invention relates to compositions comprising factor VII or a factor VII-related polypeptide and tranexamic acid, and the use thereof for treating bleeding episodes.

Disclosed are delayed release oral tranexamic acid formulations and methods of treatment therewith.

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

The invention discloses a preparation method of a polypeptide silk facial mask, which comprises the steps of fully mixing polypeptide powder and silk protein nutrient solution and cooling. Polypeptide powder is mainly composed of aloe vera, carnosine, oligopeptide, soluble collagen, 2‑o‑ethyl ascorbic acid, betaine, trehalose, niacinamide, allantoin; the protein nutrient solution of silk is mainly composed of water, glycerin, Propylene glycol, butylene glycol, malto-oligosaccharide glucoside, hydrogenated starch hydrolyzate, glycerol polymethacrylate, PVM / MA copolymer, carbomer, sodium hyaluronate triethanolamine, baobab pulp extract, tranexamic acid , Centella asiatica extract, dipotassium glycyrrhizate and other skin conditioners or moisturizers. Through the combination of polypeptide powder and silk protein liquid, it can effectively give fresh nutrition to the skin, promote the skin repair process, strengthen the nutrient absorption capacity, deeply nourish, smooth and rejuvenate the skin, and make the skin elastic.

Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

Process for the industrial synthesis of compounds of formula (I): wherein R and R' which are the same or different, each represent linear or branched (C1-C6)alkyl. Application to the synthesis of bivalent salts of ranelic acid and more especially strontium ranelate and its hydrates.

The invention discloses a medicinal sustained-release and hemostatic composition and a preparation method thereof, which belong to the technical field of novel hemostatic materials. The medicinal sustained-release and hemostatic composition comprises the composition of a medicament-loaded chitosan microsphere, chitosan and hyaluronic acid, wherein the medicament-loaded chitosan microsphere comprises medicinal grade chitosan and medicinal grade tranexamic acid. The novel hemostatic composition is prepared by using chitosan and the hyaluronic acid as a main hemostatic matrix, combining chitosan medicament sustained-release microsphere composite medicament, namely tranexamic acid, utilizing the special property of the chitosan with a hemostatic function and a medicament sustained-release function, and adopting the composition of the hyaluronic acid with good hemostatic function and high biocompatibility and the chitosan as the main matrix. The novel hemostatic composition has the advantages of stopping bleeding rapidly and releasing medicament / factors continuously and stably in a certain time, along with great economic and social benefits.

For defects that existing hemostasis research and products cannot intelligently perform self-propelling or cannot be driven to forward deep in the wound under the action of external field force, the invention provides a preparation method for a janus structure based rapid hemostatic agent having a directional propulsion function. The preparation method includes performing esterification on microporous starch to unidirectionally grow calcium carbonate particles so as to obtain esterified microporous starch / calcium carbonate Janus particles; fixedly assembling thrombin on the surfaces of the esterified microporous starch / calcium carbonate Janus particles to obtain esterified microporous starch / calcium carbonate Janus particles assembled with the thrombin; mixing the esterified microporous starch / calcium carbonate Janus particles assembled with the thrombin and protonated tranexamic acid powder so as to obtain the janus structure based rapid hemostatic agent having a directional propulsion function. Through the formation of the biphasic heterogeneous Janus structure, the unidirectional and intelligent self-propulsion of hemostatic starch can be realized by cooperating with the protonated tranexamic acid, so that rapid three-dimensional hemostasis on deep wounds, penetrating wounds and irregular wounds such as aortic / venous rupture can be realized.

The invention belongs to the technical field of cosmetics, and discloses a skin care substrate with long acting moisturizing and whitening effects and preparation and application of skin care substrate. The skin care substrate is prepared from the following components in mass percent: 10%-20% of tremella polysaccharide, 5%-10% of glycosphingolipid, 10%-20% of saccharide isomerate, 5%-10% of nicotinamide, 3%-6% of alpha-arbutin, 3%-6% of tranexamic acid, 1%-3% of ADS-Oligonol and balance of water. The skin care substrate disclosed by the invention has obvious long acting moisturizing and skin whitening effects and can make the skin moisturized and bright white by persistent use.

A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with (B) at least one member selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinols, linoleic acid, tranexamic acid, salts of these, Chamomilla recuita extract, and Ubiquinone.

The invention discloses a moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition. The composition is mainly prepared from the following raw materials: raspberry ketone glucoside, arbutin, matrine, fructo-oligosaccharide, tea tree oil, dipotassium glycyrrhizinate, an extracting solution of leaf of Tasmanian bluegum, tea polyphenol, a peony root extract, tremella polysaccharide, hyaluronic acid with low molecular weight, hyaluronic acid with high molecular weight, transparent xanthan gum, zinc gluconate, Carbomer 940, hydroxyethyl cellulose, 1,3-butanediol, nicotinamide, D-panthenol, tranexamic acid, vitamin C ethyl ether, triethanolamine, an emulsifier, water, and the like. The moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition has the beneficial effects that the composition is rich in plant essence, is reasonable in proportioning and can achieve the effects of effectively comforting and smoothening pores, cleaning hair follicles, balancing grease excretion, promoting wound healing and ensuring no pockmarks after healing and low recurrence probability; besides, the composition is also rich in moisturizing ingredients, so that the skins can be hydrated and bright, fine lines can be reduced and smooth and fair skins can be restored after the composition is used for a long term.

Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

The invention provides whitening essence and a preparation method thereof. The whitening essence consists of the following components of glycerine, 1,3-butanediol, sodium hyaluronate, EDTA-2Na, polyglycerol-10, sodium polyacrylate, xanthan gum, hydroxyacetophenone, dipotassium glycyrrhizinate, hydrolyzed sclerotium gum, gluconic acid sodium salt, glycereth-26, caprylhydroxamic acid, glycerol caprylate, 3-o-ethyl ascorbic acid, tranexamic acid, ceramide, phenethyl resorcinol, diglucosyl gallic acid and water. The whitening essence disclosed by the invention can refrain conversion of tyrosine tomelanin before the tyrosine is in preparation of conversion to the melanin, so that the activity of the tyrosinase is also high, generation of more melanin cannot be caused, and transfer of skin melanin can also be restrained. Besides, the whitening essence has powerful antioxidant ability, has light protection effects on skin, can control dermatitis, and is a whitening product most comprehensivein action mechanism at present, so that whitening effects can be achieved.

The invention discloses a medicinal toothpaste composition which comprises the following raw materials in percentage by weight: 0.01%-0.05% of sodium guaiazulene sulfonate, 0.1%-0.5% of paeonol, 0.1-0.5w / w% of allantoin, 0.1-0.5w / w% of tranexamic acid, and toothpaste matrix on the basis of the total weight. In addition, the invention further discloses a preparation method of the medicinal toothpaste composition and applications in resisting bacteria, diminishing inflammation, easing pain, shortening the treatment course of dental ulcer, and promoting oral wound healing.

The present invention relates to an inhibitor for melanin which contains tranexamic acid and niacinamide as active ingredients for inhibiting the formation of melanin cells in the skin, and a cosmetic composition containing the inhibitor for melanin as an active ingredient for relieving liver spots, blemishes, freckles and inflammatory hyperpigmentation, improving skin tone and texture, and skin whitening.

A bloating ameliorant, a lymphatic vessel activator and a VEGFC production promoter comprising a tranexamic acid amide derivative and / or salt thereof.

The invention provides toothpaste with hemostasis and gum protection functions and a preparation method of the toothpaste. The toothpaste comprises, by weight, 0.03-1.0% of panax notoginseng extract, 30-55% of abrasives, 15-30% of wetting agents, 0.6-1.5% of adhesives, 2-2.7% of foaming agents and water. The preparation method includes the steps of mixing panax notoginseng saponins, tranexamic acid, the abrasives, the wetting agents, the adhesives and the water according to the weight percentage, conducting stirring and grinding for 25-40 minutes, conducting vacuum degassing, and obtaining a toothpaste body. By means of the combined application of the panax notoginseng extract and tranexamic acid, the toothpaste can have the enhanced hemostasis and gum protection functions.

The invention discloses a process for producing tranexamic acid, wherein p-aminomethyl benzoic acid raw material is hydrogenised, and the hydrogenization liquid is neutralized to pH7-7.5 through barium carbonate, after filtering, the solution is condensed to 10 gram molecule p-aminomethyl benzoic acid reaction liquid of 5l, then charge raw materials by the portion ratio of ammonia cyclohexyl-methane carboxyl acid sym-form liquid (V) : barium hydroxide (W) : water (W) : ethanol (V) = 1:0.5-1.5:2-3.5:1.5-3, elevating the temperature to 230-260 deg. C, the pressure being 2.9-4.8.0Mpa, reacting time being 7.5-10 hours, after reaction charging water and elevating the temperature to 60-70 deg. C, neutralizing through carbon dioxide till pH=6-7.5, filtering and adjusting pH=5.2-5.5 through sulfuric acid, stewing, charging right amount activated charcoal, boiling and decolorizing, filtering, filter cake washing, condensing, charging ethanol for recrystallization, cooling down to 8-12 deg. C, filtering, washing crystallization by ethanol, filter cake drying to obtain tranexamic acid.

The invention discloses a composition for improving skin color and a whitening cosmetic. The composition comprises tranexamic acid, acetyl chitosamine and beta-nicotinamide mononucleotide. The tranexamic acid, the acetyl chitosamine and the beta-nicotinamide mononucleotide are compounded, the beta-nicotinamide mononucleotide is combined with the tranexamic acid and the acetyl chitosamine, pigmentation caused by ultraviolet rays or other skin irritation can be inhibited, and skin pigmented spots related to pigmentation are effectively prevented or improved. The acetyl chitosamine can improve transdermal absorption of effective components such as the tranexamic acid and the beta-nicotinamide mononucleotide, has a whitening effect, and can achieve a synergistic whitening effect when being used together with the tranexamic acid and the beta-nicotinamide mononucleotide, so that the tranexamic acid, the acetyl chitosamine and the beta-nicotinamide mononucleotide can achieve whitening and brightening effects at a low concentration, and are stable, safe and non-irritant.

The invention provides a medical sodium alginate gel microsphere and a preparation method and application of the medical sodium alginate gel microsphere. The medical sodium alginate gel microsphere consists of a composite medicine carrier and a water-insoluble medicine; the medicine is coated with the composite medicine carrier; and the composite medicine carrier is an ion crosslinking agent-sodium alginate-divalent metal ion, wherein the ion crosslinking agent is 4-aminomethylbenzoic acid or tranexamic acid. The preparation method comprises the following steps of: (1) mixing ion crosslinking agent aqueous solution with divalent metal ion solution in the same volume to obtain composite solidifying liquid; (2) dispersing medicine powder or an agent into sodium alginate aqueous solution; uniformly mixing; dropwise adding the mixture into the composite solidifying liquid obtained in step (1) through a high-voltage static droplet generating device or a syringe needle, so that the mixture drops are solidified into spheres; and (3) dehydrating gel microspheres which are washed with the distilled water; and drying at normal temperature. The medical sodium alginate gel microsphere can be used for treating tuberculosis, endocrine disease and tumor, and also can be used for treating local acute hemorrhage and chronic errhysis.